A unique collaboration between electrical engineers and ophthalmologists solves clinical, computational challenges.
US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...
The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...
Faricimab demonstrated noninferior vision gains and improved anatomical outcomes among patients with diabetic macular edema ...
The FDA has expanded the labeling for Izervay (avacincaptad pegol) to include longer-term administration for geographic ...
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
The US Food and Drug Administration (FDA) approved expanding the prescribing information for Japanese drugmaker Astellas ...
H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...
Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAYtm ...
Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...
Here's what macular degeneration is, what causes it and how you can expect it to be treated if it affects you or a loved one.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果